Clinical Trial Of Plasma Resistin In Type 2 Diabetes Patients

Objectives:1. To determine the serum resistin level in type 2 diabetes patients so as to evaluate its relativity with various metabolic indexes. The metabolic indexes include HOMA-IR, BMI, BF%, FG, 2hPG, 2h INS, HbA₁C, CRP, blood pressure and blood lipid spectrum. We investigated the relation of resistance with obesity and insulin resistance , as well as the probable effect on the development of type 2 diabetes.2. To ensure the effect of Rosiglitazone on the changes of plasma resistance level, glucose and lipid metabolism in type 2 diabetics, so as to provide the evidences for the pharmacological mechanism of the drug, we studied changes of the biochemical indexes of the diabetes patients given Rosiglitazone Tartrate treatment for 12 weeks.Methods:1. Physical examination was given on every subject with history of disease recorded, blood sample taken. All the patients were treated with Rosiglitazone Tartrate for 12 weeks.2. Plasma resistin level was detected with ELISA method;Blood lipid, liver and kidney function panel detested with enzyme method. Blood sugar detected with the glucooxidase method;Serum insulin was determined with the radio immunity method. Blood CRP level with immunal turbidity method.3. Evaluate the insulin resistance level with the homeostasis model (HOMR-IR).HOMA-IR= ( FINS[uU/mL]xFPG[mmol/L]) 122.54. The subjects were divided into two groups according to two methods independently. Obesity group and normal weight group come out by means of BMI. The modest insulin resistance and severe insulin resistance are distinguished by HOMA-IR.5. All data was analyzed with SPSS 11.0 software. When comparing two groups,an Independent-Samples T test was used, and analysis of correlation was performed using Pearson correlation. When comparing all parameters measured before and after treatment, a Paired-Samples T test was used.Results:1. The indexes including age, height, systolic blood pressure, diastolic blood pressure between obesity and non-obesity have no significant difference.(P>0.05)2. There was significant difference of the biochemical indexes including FPG, FINS and HOMA-IR between the obesity and non-obesity group.( PO.05) The level of the obesity is lower than that of non-obesity. No difference was observed in biochemical parameters including 2hPG, HbAiC, 2hINS, TC, TG, HDL-C, LDL-C and CRP between the two groups. The level of resistin of non-obesity group is significantly lower than that of obesity.3. Similarly, no difference was observed about the physical parameters between the modest IR group and the severe IR group.CP>0.05) But BMI,BF% and HOMR-IR of the former group is significantly lower than that of the latter.(P<0.01)4. The modest IR group has significant lower level of HbAiC, TG , FBG, FINS and resistin than that of the severe IR group(P<0.05). About the 2hBG, 2hTNS,TC,HDL-C,LDL-C,CRP,no difference was observed (P>0.05).5. The correlation analysis of the pretreatment and after treatment with Rosiglitazone Tartrate showed : The level of The HOMR-IR has no significant correlation with blood level of SBP, DBP, TC, TG, LDL-C, HDL-C, HbAjC , 2hPG , CRP (P>0.05), but has a positive correlation with BML BF%> FPG> FINS> 2hINS and resistin.6. The correlation analysis of the pretreatment and after treatment with Rosiglitazone Tartrate showed: The level of resistin has no significant correlation with blood level of SBP, DBP, TC, TG, LDL-C, HDL-C, HbAiC , 2hPG , CRP (P>0.05), but has a positive correlation with BML BF%^ FPG^ FINS> 2hINS and HOMA-IR.7. Plasma resistin level of the patients after the treatment with Rosiglitazone islower than that before the treatment significantly. HOMA-IR and the level of FPG, 2hPG , HbAiCTG, LDL-C all reduced significantly after the treatment . HDL-C improved significantly after the treatment but BMI, DBP, CRP has no difference.Conclusions:1. Plasma resistin level is correlated with obesity and insulin resistance positively in type 2 diabetes. That is, level of plasma resistin will increased with the body fat and BMI. More severe the ER, higher the resistin level.2. HOMA-IR and plasma resistin level reduced significantly after 12 weekstreatment of Rosiglitazone. Meanwhile the study showed the lipid metabolism and the blood pressure have been improved after the treatment. Rosiglitazone can enhance the insulin sensitivity and improve the dyslipidemia state of type 2 diabetes.